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Abstract
Background: Neuropathological, animal, and cell culture studies point to a role for the body's
own endogenous cannabinoids (eCBs) system in Alzheimer's disease (AD) pathology and
treatment. To date, no published studies have investigated the potential utility of circulating eCBs
as diagnostic biomarkers for AD or the impact of central eCBs on cognition.
Results: In comparison with healthy controls, there were no significant differences in measured
eCB concentrations in plasma samples from patients with AD. Detectable eCBs in cerebrospinal
fluid (CSF) had no relationship to cognitive performance in healthy controls at risk for AD. In
pooled plasma samples, an inverse correlation was observed between plasma levels of the eCB 2-
AG (2-arachidonoylglycerol) and TNF-α (r = -0.41, p < 0.02).
Conclusion:  These results suggest that circulating endocannabinoids do not have utility as
diagnostic biomarkers for AD and do not have a robust correlation with cognitive performance.
Circulating levels of 2-AG may downregulate TNF-α production.
Background
The known components of the body's endocannabinoid
(eCB) system include at least two biolipids structurally
identified as N-arachidonoylethanolamide (AEA) and 2-
arachidonoylglycerol (2-AG) produced "on-demand"
from cell membrane precursors in a variety of cell types
including both neurons and immune-competent cells in
the periphery (B cells, T cells, monocytes/macrophages)
and central nervous system (microglia, astrocytes); degra-
dative enzymes; and at least two cannabinoid receptors
(CB1 and CB2) [1]. Several in vitro experiments suggest that
eCBs act as immune modulators, generally through exert-
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ing control over inflammatory cytokine production via
the CB2 receptor [2-4]. However, it is not yet clear whether
circulating eCBs exert control over the inflammatory sys-
tem in vivo.
Recent in vitro and in vivo studies implicated the eCB sys-
tem in Alzheimer's disease (AD) pathophysiology and
there is a burgeoning sense of excitement about the poten-
tial role for eCB system interventions in disease modifica-
tion (for a recent review see Koppel 2008) [5-11].
Perturbations in plasma and CSF endocannabinoids have
been detected in several psychiatric and neurologic disor-
ders including schizophrenia[12,13], multiple sclero-
sis[14], depression[15], migraine headaches[16,17], and
eating disorders[18]. To date, no published studies have
investigated plasma levels of eCBs in AD.
While the effects of administered Δ9 -THC (acting at the
neuronal CB1 receptor) on verbal learning and memory
are well established [19], the relevance of eCBs acting on
the same receptor to learning and memory is not clear.
Acute and chronic use of marijuana impair immediate
recall, short-term memory, and memory retrieval [20]. In
vitro experiments suggest that eCBs may have a more salu-
tary effect; they promote changes in neural activities
related to memory, with a potential role in long-term syn-
aptic plasticity [21]. However, in a stress model of depres-
sion in mice, reductions in hippocampal 2-AG levels were
associated with deficits in behavioral flexibility (suggested
to be related to the inability to forget), implicating hip-
pocampal endocannabinoid signaling in the "pruning" of
normative memory systems [22]. To date, no published
reports establish the impact of central concentrations of
eCBs on human cognition.
In a case-control study we compared circulating levels of
plasma eCBs in AD and elderly controls and explored the
relationship between plasma eCBs, TNF-α and C-reactive
protein in order to determine whether circulating eCBs
influence inflammatory biomarkers. Previous experi-
ments in cell culture have demonstrated that synthetic
cannabinoids downregulate TNF-α in a concentration
dependent manner,[2] and we wondered whether that
might also be the case with endogenous cannabinoids in
vivo. We also wondered whether eCBs might have utility as
general markers of inflammation, and for that reason
chose to investigate their relationship with C-reactive pro-
tein. In a study of a separate cohort of healthy normal con-
trols we examined the impact of central (CSF) levels of
eCBs on cognition.
Methods
AD subjects and elderly controls
Late-onset (over 65 years) AD subjects and elderly con-
trols (over 65) were recruited from the Litwin-Zucker
Research Center for the Study of Alzheimer's Disease
(LZRC). The research was approved by the North Shore-
LIJ institutional review board. Informed consent was pro-
vided by subjects, and where appropriate, health care
proxy as determined by the institutional review board. All
AD subjects met DSM IV [23] and NINCDS-ADRDA [24]
criteria for Alzheimer's disease. Elderly controls (without
a subjective cognitive complaint) required a score of 28 or
higher on the Folstein MMSE. Cases and controls were
excluded if they had history of Schizophrenia, Bipolar dis-
order, Major Depression, Eating Disorder, autoimmune
disease, or malignancy, which could conceivably alter eCB
concentrations. In order to isolate plasma and protect
from enzymatic degradation of eCBs, in all subjects
approximately 40 cc of blood was collected in the morn-
ing by venopuncture, spun for 3 minutes within 5 min-
utes at 7200 RPM to facilitate plasma extraction, and flash
frozen at -80°C. Samples were transferred to the Feinstein
Biorepository and LZRC labs for DNA extraction and
amplification as well as cytokine analysis; the North
Shore-Long Island Jewish Core Laboratories for C-reactive
protein analysis; and were shipped overnight on dry ice to
Indiana University for eCB analysis.
Cognitive controls
Subjects were recruited from the LZRC as part of a longi-
tudinal study investigating CSF biomarkers in cognition
and AD. The research was approaved by the North Shore-
LIJ institutional review board. All subjects provided
informed consent. The majority of these subjects had a
positive family history of AD, but did not have cognitive
complaints at the time of examination, and none met cri-
teria for dementia. Each subject in the study was adminis-
tered the following cognitive tests over two days: Mini
Mental State Exam (global cognition), Selective Remind-
ing (total recall), Logical Memory I (episodic memory),
Trail Making A and B (speed of processing), N Back (exec-
utive functioning), Letter and Semantic Fluency (language
production and speed)[25].
Lumbar puncture (LP) was performed on one of the two
days of testing.
After routine medical and physical assessments, LP was
performed in a sitting or lateral decubitus position. Fol-
lowing sterile preparation and local anesthesia with 4%
lidocane topical cream and 1% lidocaine subcutaneous
injection, a 4 cm long, 20-gauge cutting-tip needle was
used as an introducer in the L3-L4 or L4-L5 interspace.
Next, a 25-gauge, Whiteacre-point spinal needle was
inserted through the introducer and placed in the thecal
sac. After fluid return was established, the spinal catheter
was connected to a 5 or 10 mL syringe via a polypropylene
tube. Gentle negative pressure sufficient to remove CSF at
a rate of approximately 2 mL/min was then applied byLipids in Health and Disease 2009, 8:2 http://www.lipidworld.com/content/8/1/2
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syringe and approximately 25–30 mL of clear spinal fluid
was removed from each subject. CSF was then frozen and
stored at -80°C and shipped overnight on dry ice to Indi-
ana University for eCB analysis.
Drugs and reagents for eCB quantification
High performance liquid chromatography (HPLC) grade
water, methanol, and acetonitrile used for mass spectro-
metric studies were purchased from VWR international,
Plainview, NY. Mass spectrometry/HPLC grade acetic acid,
formic acid, and ammonium acetate were purchased from
Sigma-Aldrich. [2H8] N-arachidonoyl ethanolamine (D8-
AEA) was purchased from Cayman Chemical (Ann Arbor,
MI).
Lipid extraction and endocannabinoid quantification 
methods
Lipid extractions were performed on human plasma with
the addition 9.5 milliliters of a 1:1 mixture of methanol
and acetonitrile to each 1.5 ml of plasma. Lipid extracts of
cerebral spinal fluid (CSF) were made by first adding 9.0
milliliters of a 1:1 mixture of methanol and acetonitrile to
1.0 ml CSF. An internal standard of 50 picomoles of [2H8]
N-arachidonoyl ethanolamine was spiked into each sam-
ple to measure recovery. This solution was vortexed for 1
minute then underwent centrifugation at 19,000 × g at
24°C for 20 minutes. The supernatant was diluted with
HPLC water to reach a concentration of 25% organic. Lip-
ids were partially purified from plasma on C8 solid phase
extraction columns from which the final eluent of 100%
methanol was further extracted on C18 solid phase extrac-
tion columns. Lipids were partially purified from CSF on
C18 solid phase extraction columns only. In brief, each
500 mg (plasma) or 100 mg (CSF) column was condi-
tioned with 5.0 ml methanol and 2.5 ml water followed
by loading of the water/supernatant solution. Columns
were then washed with 2 ml water and 1.5 ml 55% meth-
anol. Compounds were eluted with 1.5 ml 100% metha-
nol. The final elution from the C18 column was used for
analysis of anandamide and 2-AG.
Rapid separation of analytes was obtained using 20 μl
injections of the 100% methanol elution (Agilent 1100
series autosampler, Wilmington, DE) onto a Zorbax
eclipse XDB 2.1 × 50 mm reversed phase column. Gradi-
ent elution using mobile phase A of 20% methanol, 1 mM
ammonium acetate and 0.5% acetic acid and mobile
phase B of 100% methanol, 1 mM ammonium acetate
and 0.5% acetic acid (200 μl/min) was formed under
pressure on a pair of Shimadzu (Columbia, Maryland)
10AdVP pumps. Mass spectrometric analyses were per-
formed with an Applied Biosystems/MDS Sciex (Foster
City, CA) API 3000 triple quadrupole mass spectrometer
and an API 4000 QTRAP that were both equipped with an
electrospray ionization source. Levels of each compound
were analyzed by multiple reactions monitoring (MRM)
on the LC/MS/MS systems as previously reported [26].
Mass spectrometric conditions were optimized for each
compound using direct flow injection of synthetic stand-
ards of each compound.
TNF-α/C-reactive protein
Plasma TNF-α ELISA was performed at the LZRC using R
and D Systems Quantikine High Senstivity TNF-α/
TNFSF1A Immunoassay for serum and plasma
(#HSTAOOD). C-reactive protein was quantified with an
immunoturbidimetric assay.
Statistical analysis
For endocannabinoid quantification, we compared AEA
and 2-AG values between AD subjects and controls using
a non-paired t test. We correlated AEA and 2-AG values
with CRP and TNF-α using Pearson's r. One subject,
whose 2-AG levels were over three and a half standard
deviations from the mean, was excluded from analysis.
For analysis of cognition, we correlated 2-AG values with
cognitive test performance using Spearman's rank order
method so as to reduce the chance that outliers might
"drive" a finding.
Results and discussion
Concentrations of AEA and 2-AG were successfully quan-
tified in all plasma samples assayed. There were no signif-
icant differences in mean plasma concentrations of either
AEA or 2-AG between AD subjects (N = 19, mean age 77.3,
53% female) and elderly controls (N = 12, mean age 73.4,
58% female) (AD:: AEA: 1.58 pmol/ml+/- 0.82; 2-
AG:13.5 pmol/ml +/- 8.4; controls::AEA: 1.87 pmol/ml+/
-0.87; 2-AG: 11.0 pmol/ml +/- 8.2)(Figure 1). There was
no significant correlation between either AEA or 2-AG and
C-reactive protein concentrations. There was a significant
inverse correlation between 2-AG (but not AEA) concen-
trations and TNF-α concentrations (Pearson r = -0.41, p <
0.02) (Figure 2).
In CSF, 2-AG was successfully quantified in 35 subjects
(mean 2-AG = 0.205 pmol/ml +/- 0.116; range 0.027–
0.714). AEA was not detected in any CSF samples. The
mean age of subjects was 62.7+/-8.0 yrs, and 71% were
female. There was no significant correlation found
between CSF 2-AG concentrations and any measured
domain of cognition.
Conclusion
In a sample of 19 subjects with AD and 12 elderly con-
trols, we found no significant differences in concentra-
tions of plasma eCBs. An argument could be made that
this study was not sufficiently powered to detect differ-
ence. However, significant alterations in concentrations of
plasma eCBs have been demonstrated in similarly sizedLipids in Health and Disease 2009, 8:2 http://www.lipidworld.com/content/8/1/2
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samples of patients with other neuropsychiatric condi-
tions. In a sample of 12 women with bulimia nervosa, 15
women with anorexia nervosa, and 15 healthy women, a
significant increase in plasma AEA was reported in both
bulimic and anorexic patients compared with controls;
leptin concentrations were significantly inversely corre-
lated with AEA concentrations in both anorexic patients
and healthy controls [18]. Plasma concentrations of AEA
were found to be significantly increased in schizophrenic
patients in a sample of 12 patients with schizophrenia and
20 healthy controls [12].
Although a larger study would be necessary to conclu-
sively dismiss any impact of AD pathology on circulating
eCBs, our aim was to evaluate the utility of eCBs as diag-
nostic biomarkers for AD. There was sufficient power in
the present study to detect a clinically useful discrepancy
in eCB plasma concentrations had one existed in the pop-
ulations represented by these samples. While this study
does not support the utility of eCBs as diagnostic biomar-
kers of disease state in AD, longitudinal studies are
required to evaluate whether perturbations in eCBs occur
over the course of disease, and whether they are associated
with particular presentations or rates of disease progres-
sion.
Elevations in inflammatory plasma proteins, most nota-
bly C-reactive protein, have been found to be associated
cross-sectionally and prospectively with AD [27]. For this
reason we chose to investigate the relationship between
eCBs (as a potential biomarker for AD related inflamma-
tion) and C-reactive protein. Of note, in our plasma AD
sample we did not find any significant differences in levels
of C-reactive protein between AD patients and controls
(data not shown). The relationship between eCBs and C-
reactive protein might be investigated in samples with ele-
vated levels of C-reactive protein, as there may be correla-
tions in situations of systemic immune response. In order
to elucidate the relationship between circulating eCBs and
cytokines, we chose to focus on TNF-α as the preponder-
ance of in vitro data seems to support the notion that eCBs
exert some control over its production via the CB2 recep-
tor. For instance, 2-AG inhibits the production of TNF-α
production in both lipopolysacharide-stimulated mouse
macrophages [28] and lipopolysacharide-stimulated
microglial cells [29]. Most studies suggest a suppressive
role for 2-AG in immune response, and our observation of
an inverse correlation between circulating 2-AG and TNF-
α would support this contention. It is important to note
that the levels of TNF-α detected in our samples were very
low, (mean 1.19 pg/ml +/- 0.55). There is probably very
little physiologic relevance to these concentrations of
TNF-α; however, for AD, a condition of at least local
inflammation, 2-AG may play a crucial role in modifying
immune response via its effect on TNF-α production. A
recent study of signaling proteins that predict clinical AD
has identified TNF-α underproduction as a risk factor for
AD [30]; although very speculative, it is conceivable that
2-AG may play some role in this. The impact of circulating
plasma eCBs on other cytokines is unclear, as is the influ-
ence of parenchymal eCBs on cytokines in regions of
inflammation in brain. Further in vivo research is required
to clarify these relationships.
There is little doubt that the active cannabinoid constitu-
ent  Δ9-THC impacts learning and memory. Consistent
with this, CB1 receptor localization has revealed abundant
expression in hippocampus, cerebral cortex, cerebellum,
Plasma concentrations of 2-AG and AEA in Alzheimer's disease subjects (AD) and elderly controls (EC) Figure 1
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and basal ganglia [31]. In the human cortex, density of
receptor expression is highest in temporal and frontal
lobes, and asymmetric, with increased receptor expression
in the left hemisphere suggesting a relationship with ver-
bal language and memory systems [32]. CB1 receptors in
hippocampus and neocortex are distinctly expressed by
GABAergic interneurons, and interact with endocannabi-
noids produced in post-synaptic neurons in a retrograde
manner, with resultant depolarization-induced suppres-
sion of inhibition [33]. As modulation of inhibition gen-
erally has effects on long-term potentiation at excitatory
synapses, and as the hippocampus plays such a crucial
role in the anatomy of memory, the endocannabinoid sys-
tem has become a focus of research interest in cognitive
neuroscience. As adumbrated above, the direction of the
relationship between eCBs and cognition remains
unclear. Our failure to find an impact of CSF 2-AG con-
centrations on normative cognition does not necessarily
mean that levels of eCBs in brain do not impact cognitive
performance; what is seen in the CSF may not reflect what
is present in hippocampus. In plasma, the mean circulat-
ing levels of 2-AG in our AD and controls samples were
nearly 60 times those detected in the CSF of subjects
undergoing cognitive testing described above (where AEA
was not detected at all), most likely representing a greater
proliferation of immune competent cells producing eCBs
in plasma. eCBs may also exert an influence over cogni-
tion only in the context of dramatic overproduction, as
may be the case in neuroinflammatory diseases such as
AD. Additionally, our cognitive tests were somewhat cir-
cumscribed and other specific tests might be more sensi-
tive at detecting cannabinoid-influenced performance.
Future studies will be required to answer these questions.
Conclusion
In summary, we did not find evidence suggesting a direct
relationship between the eCB system and AD. The poten-
tial value of eCB quantification for AD and the functional
relevance of eCBS as mediators of cognitive performance
remains unclear. The neuropathological, animal, and cell
culture reports which have implicated the eCB system in
AD require focused translational experiments in clinical
research to determine what consequence, if any, eCB func-
tional variability has on cognition, disease development
or progression.
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